Pfizer To Boost Output For COVID-19 Oral Treatment With Novasep Deal
Novasep announced an agreement with Pfizer Inc (NYSE: PFE) to help the global production of the COVID-19 pill, paxlovid.
As part of the letter of intent signed between the two parties, Novasep will manufacture the active pharmaceutical ingredient (API) for the oral protease inhibitor against COVID-19.
The technical transfer, on-site development, and equipment installation will begin immediately.
Related: Canada Approves Pfizer's At-Home COVID-19 Antiviral Treatment, But Deliveries Delayed.
Novasep will add its Mourenx manufacturing site in France to the paxlovid global supply chain as early as Q3 2022.
Further expansion to other Novasep facilities and significantly increased volumes in 2023.
"Novasep will produce API for use in our manufacturing network, expected to contribute to the overall (global) effort to produce 120 million courses of treatment in 2022,"
Reuters reported quoting Pfizer, the deal is part of its plan to invest €520 million ($594 million) in France over the next five years.
Novasep plans to recruit more than 40 additional employees at the Mourenx site.
Price Action: Pfizer shares are down 1.18% at $54.30 during the premarket session on the last check Tuesday.
See more from Benzinga
FDA Gives Back To Back Approval To Pfizer's & AbbVie's JAK Inhibitors For Atopic Dermatitis
Canada Approves Pfizer's At-Home COVID-19 Antiviral Treatment, But Deliveries Delayed
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.